Recent News
TNS for ADHD: Predictors of Treatment Response
Read more about our double-blind, sham-controlled, non-medication treatment study for ADHD
January 5, 2015 - NeuroSigma has announced the commencement of UCLA's new pediatric treatment study for ADHD using eTNS therapy.This innovative non-medication clinical study is led by James McGough, M.D., M.S., Professor of Clinical Psychiatry as Principal Investigator and Sandra Loo, Ph.D., Associate Professor, as Co-Principal Investigator, both with the David Geffen School of Medicine at UCLA and the Semel Institute. The U.S. National Institute of Mental Health (NIMH) has provided grant funding to support this double-blind controlled trial of eTNS in children with ADHD, ages 8 to 12. For more information, read the full press release here: UCLA Launches Phase II Pediatric Clinical Trial for the Treatment of ADHD with NeuroSigma's eTNS System
Researchers at UCLA aim to bring ADHD and development into focus
A risk gene for ADHD is identified by UCLA researchers
Dr. McGough describes a novel non-medication treatment approach for ADHD:
"'PET scan data that showed the immediate effects of eTNS on activity in centers in the brain associated with attention prompted our interest in exploring eTNS as a treatment for ADHD in children,' said Dr. McGough. 'There is a pressing need for non-stimulant options to manage ADHD given parental and patient preferences to avoid medication use as well as the possible side effects of these drug therapies.'"
Read about difficulties in the diagnosis of adult ADHD:
"The problem, says James J. McGough, MD, is that the criteria are based in large part on diagnosing attention deficit hyperactivity disorder in school-aged children."
